Literature DB >> 7650423

Role of T cells and cytokines in effecting fibrosis.

A E Postlethwaite1.   

Abstract

A number of humoral and cellular immune abnormalities are present in patients with early scleroderma (systemic sclerosis). Most of these abnormalities reflect ongoing autoimmune reactions of the cellular and humoral types, resulting in a variety of autoantibodies to cellular and tissue constituents. Evidence exists for a defect(s) in immunoregulation favoring excessive helper T cell activity. The presence of circulating cytokines and shed interleukin-2 receptors suggest ongoing cellular immune reactions are occurring, generating cytokines and lymphokines that are capable of effecting the vascular and fibrotic lesions that are hallmarks of the disease. Future directions for research are suggested that would focus on determining if, and at what point, fibroblasts might function autonomously to generate excessive matrix components and on determining the nature of the original antigenic stimulus that starts the scleroderma process.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7650423     DOI: 10.3109/08830189509056716

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  9 in total

Review 1.  T lymphocyte and fibroblast interactions: the case of skin involvement in systemic sclerosis and other examples.

Authors:  C Chizzolini
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Increased CD8+ T cell apoptosis in scleroderma is associated with low levels of NF-kappa B.

Authors:  Aharon Kessel; Itzhak Rosner; Michael Rozenbaum; Devy Zisman; Anca Sagiv; Zehava Shmuel; Edmond Sabo; Elias Toubi
Journal:  J Clin Immunol       Date:  2004-01       Impact factor: 8.317

Review 3.  Adult xanthogranulomatous disease of the orbit and ocular adnexa: new immunohistochemical findings and clinical review.

Authors:  J A Sivak-Callcott; J Rootman; S L Rasmussen; R A Nugent; V A White; D Paridaens; Z Currie; G Rose; B Clark; A A McNab; F V Buffam; J M Neigel; M Kazim
Journal:  Br J Ophthalmol       Date:  2006-05       Impact factor: 4.638

4.  A syndrome resembling human systemic sclerosis (scleroderma) in MRL/lpr mice lacking interferon-gamma (IFN-gamma) receptor (MRL/lprgammaR-/-).

Authors:  M Le Hir; M Martin; C Haas
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

Review 5.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

6.  The role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors (statins) in modern rheumatology.

Authors:  Przemyslaw Kotyla
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-10       Impact factor: 5.346

7.  Stimulation with type I collagen induces changes in gene expression in peripheral blood mononuclear cells from patients with diffuse cutaneous systemic sclerosis (scleroderma).

Authors:  S P Atamas; I G Luzina; J Ingels; J Choi; W K Wong; D E Furst; P J Clements; A E Postlethwaite
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

8.  Differential survival of leukocyte subsets mediated by synovial, bone marrow, and skin fibroblasts: site-specific versus activation-dependent survival of T cells and neutrophils.

Authors:  Andrew Filer; Greg Parsonage; Emily Smith; Chloe Osborne; Andrew M C Thomas; S John Curnow; G Ed Rainger; Karim Raza; Gerard B Nash; Janet Lord; Mike Salmon; Christopher D Buckley
Journal:  Arthritis Rheum       Date:  2006-07

9.  Vascular involvement in systemic sclerosis (scleroderma).

Authors:  Debendra Pattanaik; Monica Brown; Arnold E Postlethwaite
Journal:  J Inflamm Res       Date:  2011-07-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.